Hussman Strategic Advisors Inc. Purchases 42,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Hussman Strategic Advisors Inc. increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 20.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 252,000 shares of the company's stock after buying an additional 42,000 shares during the quarter. Hussman Strategic Advisors Inc. owned 0.08% of Amneal Pharmaceuticals worth $1,996,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in shares of Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after acquiring an additional 777,568 shares during the period. Barclays PLC grew its position in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after purchasing an additional 169,756 shares in the last quarter. State Street Corp increased its stake in Amneal Pharmaceuticals by 3.8% in the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company's stock valued at $29,242,000 after buying an additional 127,753 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $520,000. Finally, Geode Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after buying an additional 378,136 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX traded down $0.04 during trading on Friday, reaching $7.83. 1,313,105 shares of the company's stock were exchanged, compared to its average volume of 1,110,597. The business has a 50 day moving average price of $8.04 and a 200-day moving average price of $8.27. The stock has a market capitalization of $2.43 billion, a P/E ratio of -11.51 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.00.

Insider Buying and Selling

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the sale, the director now owns 1,888,886 shares of the company's stock, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 160,000 shares of company stock valued at $1,292,000. 26.56% of the stock is owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.